Quest diagnostics adds p-tau217 blood biomarker testing to suite of services designed to assess risk and help aid diagnosis of alzheimer's disease

Company's ad-detect™ portfolio offers ab 42/40 and other plasma biomarker testing, alongside traditional cerebrospinal fluid and genetic tests, to provide robust offering in brain health secaucus, n.j. , april 22, 2024 /prnewswire/ -- quest diagnostics (nyse: dgx), a leader in diagnostic information services, today announced the launch of a new blood biomarker test for phosphorylated tau 217, or p-tau217.
DGX Ratings Summary
DGX Quant Ranking